JAK1 and hepatocellular carcinoma: Mechanistically, it was found to suppress MASLD-HCC progression by secreting acetate, which by binding to the hepatic G-coupled-protein receptor 43 (GPR43) suppresses the activation of hepatic oncogenic IL-6/JAK1/STAT3 signaling pathways (Song et al., 2023).